Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials
Open Access
- 5 June 2017
- journal article
- review article
- Published by Wiley in BioMed Research International
- Vol. 2017, 1-10
Abstract
Cerebrolysin was reported to be effective in the neurological improvement of patients with acute ischemic stroke (AIS) in experimental models, while data from clinical trials were inconsistent. We performed a meta-analysis to explore the efficacy and safety of cerebrolysin for AIS. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials, which intervened within 72 hours after the stroke onset. We investigated the efficacy and safety outcomes, respectively. Risk ratios and mean differences were pooled with fixed-effects model or random-effects model. Seven studies were identified, involving 1779 patients with AIS. The summary results failed to demonstrate significant superiority of cerebrolysin in the assessment of efficacy outcomes of mRS and BI. Similarly, administration of cerebrolysin had neutral effects on safety outcomes compared with placebo, including mortality and SAE. However, the number of included studies was small, especially in the analysis of efficacy outcomes, which might cause publication bias and inaccurate between-studies variance in the meta-analysis. Conclusively, although it seemed to be safe, routine use of cerebrolysin to improve the long-term rehabilitation after stroke could not be supported by available evidence.Keywords
This publication has 35 references indexed in Scilit:
- Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After StrokeStroke, 2013
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Cerebrolysin in Patients With Acute Ischemic Stroke in AsiaStroke, 2012
- Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after strokeJournal of Neuroscience Research, 2010
- The “Golden Hour” and Acute Brain IschemiaStroke, 2010
- Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic windowJournal of Neural Transmission, 2005
- A peptide preparation protects cells in organotypic brain slices against cell death after glutamate intoxicationJournal of Neural Transmission, 2005
- Neuroprotective treatment with Cerebrolysin in patients with acute stroke: a randomised controlled trialJournal of Neural Transmission, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Antiapoptotic effects of the peptidergic drug Cerebrolysin on primary cultures of embryonic chick cortical neuronsJournal of Neural Transmission, 2001